Table 2.
Clinical Characteristics of Aspirin‐ Versus Non‐Aspirin‐Treated Patients After Propensity Score Adjustment
| Variables | Aspirin Group n=390 Patients | Nonaspirin Group n=615 Patients | SD |
|---|---|---|---|
| Age, y | 71.99±16.11 | 73.51±16.52 | 0.092 |
| Male sex | 53.9% | 63.5% | 0.097 |
| PSI II to III classes | 22.8% | 17.0% | 0.072 |
| PSI IV class | 58.6% | 62.0% | 0.035 |
| PSI V class | 18.6% | 21.0% | 0.030 |
| CURB‐65 I class | 30.5% | 32.8% | 0.025 |
| CURB‐65 II class | 32.4% | 40.2% | 0.081 |
| CURB‐65 III class | 16.7% | 19.7% | 0.039 |
| Chronic heart disease | 21.3% | 28.9% | 0.088 |
| Chronic hepatitis | 8.6% | 8.0% | 0.030 |
| Diabetes | 12.6% | 15.2% | 0.038 |
| Renal failure | 11.6% | 13.8% | 0.033 |
| COPD | 29.4% | 30.2% | 0.009 |
| CAP | 18.4% | 21.9% | 0.044 |
| HCAP | 81.6% | 78.1% | 0.044 |
| Neoplasm | 13.7% | 17.0% | 0.046 |
| Pleural effusion | 25.5% | 33.2% | 0.085 |
| Immunosuppressive therapy | 11.0% | 14.6% | 0.054 |
| Fever >38°C | 57.4% | 51.8% | 0.056 |
| PaO2/FiO2 ratio <300 | 4.5% | 5.0% | 0.012 |
| NIV | 0.6% | 3.5% | 0.103 |
| SOFA score >2 | 57.1% | 55.6% | 0.015 |
| Severe sepsis or septic shock | 5.6% | 5.4% | 0.004 |
| Nonfatal cardiovascular events | 6.2% | 3.3% | 0.068 |
SD <10% indicates balance. CAP indicates community‐acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare‐associated pneumonia; NIV, noninvasive ventilation; PSI, pneumonia severity index; SOFA, Sequential Organ Failure Assessment.